Cutts Briony A, Fennessy Kristy
Department of Haematology, Royal Women's Hospital, Melbourne, Victoria, Australia.
Department of Obstetrics, Joan Kirner Women's and Children's at Sunshine Hospital, Western Health, Melbourne, Victoria, Australia.
Res Pract Thromb Haemost. 2025 Feb 6;9(2):102698. doi: 10.1016/j.rpth.2025.102698. eCollection 2025 Feb.
A state of the art lecture titled, "Addressing the Perimenopause: What's Blood Got to Do with It?" was presented at the International Society on Haemostasis and Thrombosis (ISTH) Congress in 2024. Perimenopause is when fluctuations of previously cyclically regulated hormones occur prior to menopause, resulting in a number of symptoms that can negatively impact a woman's quality of life. Thrombosis and hemostasis experts are often approached to help investigate and manage clinical issues associated with perimenopause. This includes the safety of using menopause hormonal therapy in a past history or family history of venous thromboembolism, arterial thrombosis or thrombophilia, heavy menstrual bleeding, and iron deficiency anemia. A review of recent literature and clinical practice guidelines was undertaken to help determine the role of iron deficiency anemia in perimenopause, thrombotic risk in the setting of using menopause hormonal therapy, and indications for thrombophilia testing prior to commencing menopause hormonal therapy. Finally, we summarize relevant new data on this topic presented during the ISTH 2024 Congress.
一场题为“应对围绝经期：血液与之有何关系？”的前沿讲座于2024年在国际血栓与止血学会（ISTH）大会上发表。围绝经期是指绝经前先前周期性调节的激素出现波动，导致一系列可能对女性生活质量产生负面影响的症状。血栓形成和止血专家经常被要求协助调查和处理与围绝经期相关的临床问题。这包括在有静脉血栓栓塞、动脉血栓形成或血栓形成倾向的个人病史或家族病史、月经过多以及缺铁性贫血的情况下使用绝经激素疗法的安全性。我们对近期文献和临床实践指南进行了综述，以帮助确定缺铁性贫血在围绝经期中的作用、使用绝经激素疗法时的血栓形成风险，以及在开始绝经激素疗法之前进行血栓形成倾向检测的指征。最后，我们总结了在ISTH 2024大会期间提出的关于该主题的相关新数据。
